In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Buy rating on GW Pharma (GWPH – Research Report), with a price target of $232. The company’s shares closed yesterday at $152.42.
According to TipRanks.com, Kasimov is a 3-star analyst with an average return of 2.2% and a 42.6% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., BioMarin Pharmaceutical Inc., and ACADIA Pharmaceuticals Inc.
GW Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $205, representing a 34.5% upside. In a report issued on July 26, Cowen & Co. also maintained a Buy rating on the stock with a $200 price target.
The company has a one-year high of $196 and a one-year low of $90.14. Currently, GW Pharma has an average volume of 388.5K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its lead cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex.